When was Pelago Bioscience founded?

Pelago Bioscience was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is Pelago Bioscience located?

Pelago Bioscience is headquartered in Solna, Sweden.

Who is the current CEO of Pelago Bioscience?

Michael Dabrowski of Pelago Bioscience.

How many employees does Pelago Bioscience have?

As of Apr 30, 2026, the latest employee count at Pelago Bioscience is 64.

Is Pelago Bioscience a funded company?

Pelago Bioscience is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 01, 2017.

When was the latest funding round of Pelago Bioscience?

Pelago Bioscience's latest funding was a $***** Seed round on Aug 16, 2023, with participation from 1 investor.

Where does Pelago Bioscience rank among its competitors?

Pelago Bioscience ranks 36th amongst 173 active competitors, of which 44 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Kiyatec, which secured an undisclosed amount in Nov, 2025.

Who are the top competitors of Pelago Bioscience?

Pelago Bioscience's top competitors include CytoTronics, Metrion Biosciences and Kiyatec. Among them, Kiyatec secured the most recent funding round in November, 2025.

Pelago Bioscience - 2026 Company Profile, Team, Funding & Competitors

Pelago Bioscience is a seed company based in Solna (Sweden), founded in 2013. It operates as an Assay services for use in the determination and quantification of drug-target interactions. Pelago Bioscience has raised an undisclosed amount in funding from Impilo. The company has 173 active competitors, including 44 funded and 23 that have exited. Its top competitors include companies like CytoTronics, Metrion Biosciences and Kiyatec.

Company Details

Assay services for use in the determination and quantification of drug-target interactions. The company offers patented Cellular Thermal Shift Assay (CETSA) for use in determination and quantification of drug-target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. The company offers 3 assay services CETSA Classics, western blot-based detection, CETSA HT, Plate based fluorescence detection, CETSA MS, Mass spectrometry detection of target engagement on up to 6000 proteins.

Website: www.pelagobio.com/
Email ID: *****@pelagobio.com

Key Metrics

Founded Year

2013

Location

Solna, Sweden

Stage

Seed

Latest Funding Round

Seed, Aug 16, 2023, $*****

Investors

Impilo & 2 more

Ranked

36^th among 173 active competitors

Employee Count

64 as on Apr 30, 2026

Similar Companies

CytoTronics & 151 more

View Pelago Bioscience's full profile

Pelago Bioscience has raised funding over 2 rounds. Its first funding round was on Jan 01, 2017. Its latest funding round was a Seed round on Aug 16, 2023 for $*****. 1 investor participated in its latest round. Pelago Bioscience has 3 institutional investors.

Here is the list of recent funding rounds of Pelago Bioscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 16, 2023	7830083	Seed	1471701	1666627	8161762	7705296
Jan 01, 2017	6107498	Grant (prize money)	4512502	5112463	4904418	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Pelago Bioscience's funding rounds and investors

Pelago Bioscience's employee count trend

Pelago Bioscience has 64 employees as of Apr 26. Here is Pelago Bioscience's employee count trend over the years:

Employee count trend for Pelago Bioscience

Uncover Pelago Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pelago Bioscience include CytoTronics, Metrion Biosciences and Kiyatec. Here is the list of Top 10 competitors of Pelago Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.7M	Anzu Partners, BoxOne Ventures & 1 others	59/100
2nd	Metrion Biosciences 2015, Cambridge (United Kingdom), Series B	CRO specializing in ion channel screening, cardiac safety profiling and drug discovery services	$8.44M	Gresham House Ventures, o2h ventures & 23 others	57/100
3rd	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	56/100
4th	Anabios 2009, San Diego (United States), Series B	Human tissue and cell provider accelerating drug discovery and development	$24.8M	Tech Coast Angels, Principia SGR & 8 others	50/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	47/100
6th	Cellply 2013, Bologna (Italy), Series A	Developer of in-vitro diagnostic products for the detection of cancer	$8.05M	LIFTT, Indaco & 13 others	47/100
7th	ImmuONE 2019, Hatfield (United Kingdom), Seed	CRO focused on innovative solutions for inhalation safety	$4.53M	Mercia, Pioneer Group & 1 others	43/100
8th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	42/100
9th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	41/100
10th	Alomone 1989, Jerusalem (Israel), Unfunded	Supplier of ion channel, GPCR and neural signaling tools	-	-	41/100
36th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	35/100